Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | HuCCT1 is a human intrahepatic cholangiocarcinoma cell line established from malignant cells collected from ascitic fluid. The donor had a moderately differentiated adenocarcinoma arising from the intrahepatic bile duct. HuCCT1 cells display epithelial-like morphology and grow as an adherent culture. The line produces carbohydrate antigen 19-9 and carries defined alterations in KRAS, TP53, and MSH6, providing a relevant model for investigating biliary tract cancer biology, oncogenic signaling, tumor-marker secretion, therapeutic response, and mechanisms of drug resistance. |
| Tissue of Origin | Intrahepatic bile duct; primary cancer associated with the liver and biliary tract |
| Sample Type | Malignant cells isolated from ascitic fluid |
| Disease | Intrahepatic cholangiocarcinoma; moderately differentiated adenocarcinoma |
| Morphology | Epithelial-like |
| Sex | Male |
| Age at Sampling | 56 years |
| Population | Japanese |
| Year Established | 1989 |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | Biosafety Level 1 is generally applied; confirm handling requirements through a local risk assessment before use |
| Applications | 1. Intrahepatic cholangiocarcinoma biology and disease-mechanism research 2. Investigation of KRAS-driven signaling and TP53-associated phenotypes 3. CA19-9 production and biliary tumor-marker studies 4. Anticancer drug screening, combination testing, and resistance research 5. Cell proliferation, apoptosis, migration, invasion, and pathway analysis 6. Genomic, transcriptomic, proteomic, and functional screening workflows 7. Comparative studies of molecularly defined biliary tract cancer models |
| Storage Conditions | Store below −130°C; vapor-phase liquid nitrogen is recommended for long-term preservation |
| Characteristics | |
| Tumor Marker Production | Produces carbohydrate antigen 19-9 (CA19-9), including under serum-free culture conditions reported during the original characterization |
| Genetic Profile | Reported variants include heterozygous KRAS p.Gly12Asp (G12D; c.35G>A), homozygous TP53 p.Arg175His (R175H; c.524G>A), and heterozygous MSH6 p.Lys1358fs*2 (c.4071_4072insGATT). This combination supports studies of RAS signaling, altered p53 function, and DNA mismatch-repair biology. |
| Microsatellite Status | Microsatellite stable (MSS), despite the reported heterozygous MSH6 frameshift variant |
| Life Span | Continuous / immortalized |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Culture Conditions | 37°C in a humidified atmosphere containing 5% CO₂ |
| Recommended Seeding Density | A lot-specific starting density of approximately 0.8–1.4 × 10⁴ cells/cm² has been used successfully. Optimize the seeding density for the vessel, passage history, and experimental endpoint. |
| Subculturing | 1. Remove the spent medium and rinse the adherent monolayer with calcium- and magnesium-free balanced salt solution. 2. Add sufficient trypsin–EDTA solution to cover the cell layer. A formulation of 0.05% trypsin with 0.02% EDTA for approximately 10 minutes at 37°C is recommended in the general passage protocol; 0.25% trypsin with 0.02% EDTA has also been used for distributed lots. 3. Monitor detachment microscopically and avoid unnecessary exposure to the dissociation reagent. 4. Add complete medium, gently pipette to obtain an even suspension, and transfer the required aliquot to a new culture vessel. 5. Return the culture to 37°C and 5% CO₂. |
| Subcultivation Ratio | A split ratio of 1:4 is recommended |
| Thawing and Recovery | Thaw the vial rapidly in a 37°C water bath and disinfect the exterior before opening. Transfer the contents promptly into pre-warmed complete medium, remove the cryoprotectant by gentle centrifugation when required, resuspend the cells, and seed into a suitable culture vessel. Minimize the time spent in concentrated cryoprotectant and avoid harsh pipetting during early recovery. |
| Cryopreservation | A reported freezing formulation consists of RPMI-1640 containing 20% fetal bovine serum and 10% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO0998 | Human CLDN18-A2 Stable Cell Line - HUCCT1 | Inquiry |
| CSC-RR01197 | Luciferase Reporter Cell Line - HuCCT1 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.